SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
WVE

Wave Life Sciences, Inc. (NASDAQ:WVE)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$2.56-$0.16 (-5.88%)
 
Market cap
$505M
Insider Score
Health Score
Analyst consensus
Listed since
Nov 11, 2015
Market Cap$504.91M-63.7%
Revenue (ttm)$70.92M-35.1%
Net Income-$210.53M-72.6%
EPS-$1.07-42.7%
Shares Out197.23M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,279,709
Open$2.65
Previous Close$2.72
Day's Range$2.54 - $2.79
52-Week Range$2.54 - $21.73
Betan/a
AnalystsBuy
Price Target$11.75(+358.98%)
Earnings DateFeb 25, 2027

About WVE

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.

Address
733 Concord Avenue, Cambridge, MA, 02138, US
Market Cap
505 million
Employees
317
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$892.55K
Bought
$54.62M

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
4 Buy1 Hold0 SellAvg target $28.60 (+1017.2%)

5 firms rating WVE in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Fair
From WVE’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-5.88%
5 Days
-16.88%
1 Month
-24.04%
6 Months
-60.12%
1 Year
-63.69%

$WVE stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in WVE holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by WVE's directors and management

Net Shares Purchased by Insiders−9M−4.5M02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

WVE Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New WVE patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to WVE from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in WVE

IWMiShares Russell 2000 ETF$9.87M
VXFVanguard Extended Market ETF$6.21M
XPHState Street SPDR S&P Pharmaceuticals ETF$5.45M
IBBiShares Biotechnology ETF$3.43M
IWNiShares Russell 2000 Value ETF$3.38M
VTWOVanguard Russell 2000 ETF$2.98M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from WVE’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
60% of score
7.36
Analyst Ratings
40% of score
99
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
4
Sells
10
Buy Value
$54.62M
Distinct Buyers
1

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

XPHState Street SPDR S&P Pharmaceuticals ETF1.17%
WDNAWisdomTree BioRevolution Fund0.97%
SPITF/m Emerald Special Situations ETF0.97%
BBCVirtus Biotech Clinical Trials ETF0.43%
LFSCF/M Emerald Life Sciences Innovation ETF0.42%
GNOMGlobal X - Genomics & Biotechnology ETF0.41%
SBIOALPS Medical Breakthroughs ETF0.41%
OZEMRoundhill Investments - GLP-1 & Weight Loss ETF0.24%
PILLDirexion Daily Pharmaceutical & Medical Bull 3X ETF0.18%
IWCiShares Micro-Cap ETF0.12%
IHEiShares U.S. Pharmaceuticals ETF0.10%
KOMPState Street SPDR S&P Kensho New Economies Composite ETF0.05%

Weight is the stock’s share of each fund’s holdings.